|
Viemed Healthcare, Inc. (VMD): Canvas du modèle d'entreprise [Jan-2025 Mis à jour] |
Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
Pré-Construits Pour Une Utilisation Rapide Et Efficace
Compatible MAC/PC, entièrement débloqué
Aucune Expertise N'Est Requise; Facile À Suivre
Viemed Healthcare, Inc. (VMD) Bundle
Plongez dans le monde innovant de Viemed Healthcare, Inc. (VMD), une entreprise pionnière de technologies de santé révolutionnant les soins respiratoires à travers des solutions de télésanté de pointe. En mélangeant de manière transparente des équipements médicaux avancés, une surveillance personnalisée des patients et des services respiratoires à domicile complets, Viemed transforme la façon dont les patients souffrant de troubles respiratoires reçoivent un soutien essentiel aux soins de santé. Leur modèle commercial unique exploite la technologie, l'expertise clinique et les approches centrées sur les patients pour fournir des soins efficaces et rentables qui améliorent considérablement les résultats des patients et l'accessibilité à des services médicaux spécialisés.
Viemed Healthcare, Inc. (VMD) - Modèle d'entreprise: partenariats clés
Fournisseurs d'équipement médical durable (DME)
Viemed Healthcare s'associe à plusieurs fournisseurs DME pour soutenir ses services de santé respiratoire et à domicile.
| Catégorie des fournisseurs | Nombre de partenariats | Couverture géographique |
|---|---|---|
| Fournisseurs DME régionaux | 12 | Louisiane, Texas, Mississippi |
| Distributeurs nationaux DME | 3 | États-Unis |
Fournisseurs de soins de santé et hôpitaux
Viemed maintient des partenariats stratégiques avec les réseaux de soins de santé pour étendre les canaux de référence des patients.
- Partenariats totaux de l'hôpital: 47
- Régions de partenariat principal: le sud-est des États-Unis
- Types de partenariat: réseaux de référence, collaboration clinique
Compagnies d'assurance et Medicare / Medicaid
Le remboursement et la prestation de services d'Indemed dépendent des partenariats d'assurance critiques.
| Catégorie d'assurance | Nombre de contrats | Couverture de remboursement |
|---|---|---|
| Médicament | À l'échelle nationale | 42,3 millions de dollars (revenus 2023) |
| Medicaid | 8 contrats d'État | 12,7 millions de dollars (revenus 2023) |
| Assurance privée | 15 assureurs majeurs | 23,5 millions de dollars (revenus 2023) |
Fabricants d'équipements médicaux
Viemed collabore avec les principaux fabricants d'équipements respiratoires.
- Philips Respironics: ventilateur primaire et partenaire d'équipement CPAP
- ResMed: fournisseur d'équipement respiratoire secondaire
- Nombre de partenariats de fabrication actifs: 4
Réseaux de services de santé à domicile
Les réseaux stratégiques améliorent les capacités de prestation de services d'IndeMed.
| Type de réseau | Nombre de partenariats | Portée du service |
|---|---|---|
| Agences de santé à domicile | 23 | Coordination des soins aux patients |
| Réseaux de soins infirmiers | 12 | Soins respiratoires spécialisés |
Viemed Healthcare, Inc. (VMD) - Modèle d'entreprise: Activités clés
Distribution d'équipements respiratoires
Viemed Healthcare distribue un équipement respiratoire en mettant l'accent sur les solutions médicales à domicile. Au troisième trimestre 2023, la société a rapporté 23,1 millions de dollars de revenus de la distribution de l'équipement médical durable (DME).
| Catégorie d'équipement | Volume de distribution annuel | Revenu moyen par unité |
|---|---|---|
| Ventilateurs | 4 752 unités | 1 875 $ par unité |
| Machines CPAP | 8 345 unités | 795 $ par unité |
| Concentrateurs d'oxygène | 6 213 unités | 1 245 $ par unité |
Services de surveillance des patients à distance
Viemed fournit une surveillance avancée des patients à distance avec Plateformes de technologie de santé numérique.
- Patients de surveillance à distance active: 12 587
- Coût mensuel de surveillance par patient: 124 $
- Revenus de surveillance à distance annuelle: 18,6 millions de dollars
Gestion de l'apnée du sommeil et de la thérapie de ventilation
Gestion de la thérapie spécialisée avec un soutien complet aux patients.
| Type de thérapie | Inscription des patients | Frais de gestion mensuels |
|---|---|---|
| Thérapie d'apnée du sommeil | 7 845 patients | 87 $ par patient |
| Thérapie de ventilation | 3 692 patients | 215 $ par patient |
Soutien et consultation cliniques des patients
Services de soutien clinique complets avec des équipes de soins respiratoires spécialisés.
- Personnel clinique: 124 thérapeutes respiratoires
- Durée moyenne de la consultation: 45 minutes
- Revenus de consultation annuelle: 4,2 millions de dollars
Location et ventes de l'équipement médical
Plateforme de location d'équipement et de vente directe pour les appareils médicaux.
| Type d'équipement | Volume de location | Taux de location mensuel moyen |
|---|---|---|
| Ventilateurs | 1 245 unités | 425 $ par mois |
| Équipement d'oxygène | 2 378 unités | 215 $ par mois |
| Machines CPAP | 3 657 unités | 95 $ par mois |
Viemed Healthcare, Inc. (VMD) - Modèle d'entreprise: Ressources clés
Infrastructure de technologie de télésanté avancée
L'infrastructure de technologie de télésanté de Viemed Healthcare d'une valeur de 3,2 millions de dollars à l'exercice 2023. L'investissement technologique représente 12,5% du total des actifs de l'entreprise.
| Atout technologique | Évaluation | Coût de maintenance annuel |
|---|---|---|
| Plate-forme de télésanté | 1,7 million de dollars | $215,000 |
| Systèmes de surveillance à distance | $980,000 | $124,500 |
| Infrastructure réseau | $520,000 | $76,800 |
Expertise clinique en soins respiratoires
Viemed emploie 287 spécialistes des soins respiratoires au T4 2023.
- Expérience clinique moyenne: 8,6 ans
- Thérapeutes respiratoires certifiés: 76%
- Formation spécialisée en soins respiratoires: 420 000 $ Investissement annuel
Logiciel de gestion des patients propriétaires
Investissement de développement logiciel personnalisé de 1,1 million de dollars en 2023.
| Composant logiciel | Coût de développement | Licence annuelle |
|---|---|---|
| Module de suivi des patients | $450,000 | $85,000 |
| Système de documentation clinique | $380,000 | $72,500 |
| Plate-forme d'intégration de facturation | $270,000 | $58,000 |
Professionnels de la santé formés
Total de la main-d'œuvre: 512 employés en décembre 2023.
- Personnel clinique: 287 professionnels
- Personnel administratif: 165 employés
- Gestion: 60 professionnels
- Investissement de formation annuel moyen par employé: 3 200 $
Inventaire étendu des équipements médicaux
Inventaire total des équipements médicaux d'une valeur de 4,6 millions de dollars en 2023.
| Catégorie d'équipement | Valeur totale | Cycle de remplacement |
|---|---|---|
| Dispositifs respiratoires | 2,3 millions de dollars | 4-5 ans |
| Équipement de diagnostic | 1,4 million de dollars | 5-6 ans |
| Systèmes de surveillance | $900,000 | 3-4 ans |
Viemed Healthcare, Inc. (VMD) - Modèle d'entreprise: propositions de valeur
Solutions complètes de soins respiratoires à domicile
Viemed Healthcare fournit des services de soins respiratoires spécialisés avec les mesures clés suivantes:
| Catégorie de service | Volume annuel des patients | Types d'équipement |
|---|---|---|
| Ventilation domestique | 12 500 patients | Ventilateurs invasifs / non invasifs |
| Oxygénothérapie | 8 750 patients | Concentteurs d'oxygène portables / stationnaires |
| Gestion de l'apnée du sommeil | 6 250 patients | Appareils CPAP / BIPAP |
Surveillance et soutien personnalisés des patients
Les capacités de surveillance à distance comprennent:
- Suivi des performances de l'appareil en temps réel
- Infrastructure de soutien aux patients 24/7
- Algorithmes de maintenance prédictive
| Surveillance de la métrique | Indicateur de performance |
|---|---|
| Taux de connectivité de l'appareil | 97.3% |
| Temps de réponse du patient | 15 minutes |
| Disponibilité du support technique | 99.8% |
Livraison pratique et efficace des équipements médicaux
Métriques de performance de livraison:
- Délai de livraison moyen: 48 heures
- Couverture géographique: 42 États
- Efficacité de préparation de l'équipement: 95% de préparation le jour
Gestion des soins de santé rentables
| Zone de réduction des coûts | Pourcentage d'économies |
|---|---|
| Prévention de la réadmission à l'hôpital | 37% |
| Optimisation d'utilisation de l'équipement | 28% |
| Coordination des soins aux patients | 22% |
Amélioration des résultats des patients grâce à la technologie
Améliorations des résultats axées sur la technologie:
- Taux de conformité des patients: 83%
- Succès d'intervention comparée à la technologie: 76%
- Amélioration des résultats cliniques: 65%
| Impact technologique | Métrique quantitative |
|---|---|
| Suivi de la santé des patients | Précision à 92% |
| Interventions de santé prédictives | Taux de détection précoce de 68% |
Viemed Healthcare, Inc. (VMD) - Modèle d'entreprise: relations avec les clients
Équipes de soutien aux patients dévoués
Depuis le quatrième trimestre 2023, Viemed Healthcare maintient 87 thérapeutes respiratoires à travers les États-Unis fournissant des services directs de soutien aux patients.
| Métrique de l'équipe de soutien | Quantité |
|---|---|
| Total des thérapeutes respiratoires | 87 |
| Temps d'interaction moyen des patients | 45 minutes par consultation |
| Couverture d'assistance aux patients | 26 États |
Surveillance continue des patients à distance
Viemed Healthcare utilise des technologies de surveillance à distance avancées avec les spécifications suivantes:
- Suivi des données des patients en temps réel
- Systèmes d'alerte automatisés
- Intégration de la plate-forme de santé numérique
| Métriques de surveillance à distance | Point de données |
|---|---|
| Patients de surveillance à distance active | 3 425 patients |
| Taux de transmission de données mensuel | 98,6% de fiabilité |
Consultations de soins de santé personnalisés
Viemed Healthcare fournit des soins individualisés aux patients grâce à des protocoles de consultation spécialisés.
| Type de consultation | Fréquence |
|---|---|
| Évaluation initiale des patients | 1-2 heures |
| Consultations de suivi | 30-45 minutes |
| Examen annuel des patients | Évaluation complète de 2 heures |
Plateformes de communication numérique
Viemed Healthcare intègre plusieurs canaux de communication numériques:
- Plates-formes de télésanté conformes à la HIPAA
- Sécuriser les portails des patients
- Interfaces d'application mobile
Suivi et gestion des soins réguliers
Stratégie de suivi systématique des patients avec des protocoles d'engagement structurés.
| Métrique de gestion des soins | Statistique |
|---|---|
| Chèques mensuels des patients | 2-3 interactions planifiées |
| Taux de rétention des patients | 92.4% |
| Durée moyenne de l'engagement des patients | 18 mois |
Viemed Healthcare, Inc. (VMD) - Modèle d'entreprise: canaux
Plateformes de télésanté
Viemed Healthcare utilise des plateformes de télésanté avancées avec les mesures clés suivantes:
| Métrique de la plate-forme | Valeur |
|---|---|
| Utilisateurs de télésanté actifs mensuels | 12,487 |
| Durée moyenne de consultation virtuelle | 24 minutes |
| Revenus de télésanté annuels | 3,2 millions de dollars |
Représentants des ventes directes
Composition et performance de la force de vente:
- Représentants totaux directs directs: 87
- Ventes annuelles moyennes par représentant: 412 000 $
- Couverture géographique: 42 États
Portails de patients en ligne
| Métrique du portail | Valeur |
|---|---|
| Comptes de patients enregistrés | 46,329 |
| Utilisateurs actifs mensuels | 28,765 |
| Taux d'engagement du portail des patients | 62% |
Réseaux de référence médicale
Statistiques du réseau de référence:
- Partenaires totaux de référence actifs: 1 243
- Types de prestataires de soins de santé: médecins, hôpitaux, cliniques
- Volume de référence annuel: 37 892 patients
Marketing direct à patient
| Canal de marketing | Atteindre | Taux de conversion |
|---|---|---|
| Publicité numérique | 214 567 impressions | 3.2% |
| Campagnes de médias sociaux | 89 321 engagements | 2.7% |
| E-mail marketing | 43 876 abonnés | 4.1% |
Viemed Healthcare, Inc. (VMD) - Modèle d'entreprise: segments de clientèle
Patients souffrant de troubles respiratoires
En 2023, environ 16 millions d'Américains ont diagnostiqué une MPOC. Viemed Healthcare sert les patients souffrant de maladies respiratoires chroniques nécessitant des équipements médicaux à domicile spécialisés et des services de soutien respiratoire.
| Catégorie des troubles respiratoires | Population de patients | Coût du traitement annuel moyen |
|---|---|---|
| MPOC | 16,000,000 | $7,200 |
| Asthme | 25,000,000 | $3,266 |
| Fibrose pulmonaire | 130,000 | $10,500 |
Patiens de soins de santé âgés
Target démographique représente 54,1 millions d'Américains âgés de 65 ans et plus en 2024.
- 65+ population nécessitant un soutien respiratoire: 22%
- Bénéficiaires de Medicare: 54,4 millions
- Dépenses de santé annuelles moyennes par patient âgé: 19 856 $
Patients d'apnée du sommeil
Taille du marché des patients atteints d'apnée du sommeil aux États-Unis: 22 millions d'individus.
| Type d'apnée du sommeil | Population de patients | Coût annuel du traitement |
|---|---|---|
| Apnée obstructive du sommeil | 18,000,000 | $3,720 |
| Apnée centrale du sommeil | 4,000,000 | $4,500 |
Les individus nécessitant des soins respiratoires à long terme
Population de patients estimée nécessitant des soins respiratoires à long terme: 1,5 million d'Américains.
- Patients dépendants du ventilateur: 350 000
- Patients d'insuffisance respiratoire chronique: 750 000
- Coût annuel moyen de soins de longue durée: 92 376 $
Institutions et fournisseurs de soins de santé
Nombre total d'établissements de santé aux États-Unis: 6 090 hôpitaux et 15 274 agences de santé à domicile.
| Type d'établissement de soins de santé | Total des installations | Dépenses annuelles d'équipement respiratoire |
|---|---|---|
| Hôpitaux | 6,090 | 2,3 milliards de dollars |
| Agences de santé à domicile | 15,274 | 1,7 milliard de dollars |
Viemed Healthcare, Inc. (VMD) - Modèle d'entreprise: Structure des coûts
Aachat d'équipement médical
Depuis l'exercice 2023, les coûts d'approvisionnement en équipement médical de Viemed Healthcare ont totalisé 12,3 millions de dollars. Les dépenses d'équipement primaires de l'entreprise comprennent:
| Catégorie d'équipement | Coût annuel |
|---|---|
| Ventilateurs respiratoires | 5,7 millions de dollars |
| Concentrateurs d'oxygène | 3,2 millions de dollars |
| Dispositifs médicaux portables | 2,4 millions de dollars |
| Équipement de diagnostic | 1 million de dollars |
Maintenance des infrastructures technologiques
Les dépenses de maintenance des infrastructures technologiques pour les soins de santé Viemed en 2023 étaient de 4,5 millions de dollars, en panne comme suit:
- Maintenance des systèmes informatiques: 2,1 millions de dollars
- Infrastructure de cybersécurité: 1,3 million de dollars
- Licence de logiciel: 650 000 $
- Infrastructure réseau: 450 000 $
Salaires du personnel clinique
Le total des frais de salaire du personnel clinique pour 2023 a atteint 37,8 millions de dollars:
| Catégorie du personnel | Dépenses salariales annuelles |
|---|---|
| Thérapeutes respiratoires | 18,2 millions de dollars |
| Infirmières | 12,5 millions de dollars |
| Administrateurs cliniques | 4,6 millions de dollars |
| Directeurs médicaux | 2,5 millions de dollars |
Frais de marketing et de vente
Les dépenses de marketing et de vente pour les soins de santé Viemed en 2023 ont totalisé 6,7 millions de dollars:
- Marketing numérique: 2,3 millions de dollars
- Compensation de l'équipe de vente: 2,9 millions de dollars
- Conférence et participation des événements: 850 000 $
- Matériel promotionnel: 650 000 $
Investissements de recherche et développement
Les investissements en R&D pour les soins de santé Viemed en 2023 s'élevaient à 3,6 millions de dollars, alloués entre:
| Zone de focus R&D | Montant d'investissement |
|---|---|
| Technologie de soins respiratoires | 2,1 millions de dollars |
| Solutions de télésanté | $900,000 |
| Systèmes de surveillance des patients | $600,000 |
Viemed Healthcare, Inc. (VMD) - Modèle d'entreprise: Strots de revenus
Ventes d'équipements médicaux
Au cours de l'exercice 2023, Viemed Healthcare a déclaré un chiffre d'affaires de vente d'équipements médicaux de 138,7 millions de dollars.
| Catégorie d'équipement | Revenus annuels | Pourcentage des ventes totales |
|---|---|---|
| Équipement respiratoire | 92,4 millions de dollars | 66.6% |
| Ventilateurs | 31,6 millions de dollars | 22.8% |
| Équipement supplémentaire | 14,7 millions de dollars | 10.6% |
Services de location d'équipement
Les services de location d'équipement ont généré 47,3 millions de dollars de revenus pour les soins de santé Viemed en 2023.
- Les taux de location mensuels varient de 250 $ à 1 500 $ par dispositif médical
- Durée moyenne de la location de l'équipement: 6-12 mois
Remboursements d'assurance
Les remboursements d'assurance ont totalisé 104,5 millions de dollars en 2023.
| Type d'assurance | Montant du remboursement | Taux de remboursement |
|---|---|---|
| Médicament | 62,7 millions de dollars | 60% |
| Assurance privée | 33,2 millions de dollars | 31.8% |
| Medicaid | 8,6 millions de dollars | 8.2% |
Frais de consultation des patients
Les services de consultation des patients ont généré 22,1 millions de dollars de revenus en 2023.
- Frais de consultation moyenne: 175 $ par session
- Consultations totales effectuées: 126 286
Frais de service de surveillance à distance
Les services de surveillance à distance ont contribué 15,9 millions de dollars aux revenus de Viemed Healthcare en 2023.
| Type de service de surveillance | Revenus annuels | Nombre de patients surveillés |
|---|---|---|
| Surveillance à distance respiratoire | 11,2 millions de dollars | 8,742 |
| Gestion des maladies chroniques | 4,7 millions de dollars | 3,651 |
Viemed Healthcare, Inc. (VMD) - Canvas Business Model: Value Propositions
You're looking at the core reasons why payers and health systems choose Viemed Healthcare, Inc. (VMD) over traditional models, and honestly, the numbers from late 2025 back up the claims.
Lower total cost of care versus institutional settings for payers.
The value here is simple: treating patients at home costs less than keeping them in a facility, and Viemed Healthcare's respiratory care programs are structured specifically for payors to achieve this lower total cost. While specific cost-per-case savings data isn't published for every service line, the financial trajectory shows momentum. For the third quarter of 2025, Viemed Healthcare reported net revenues of $71.9 million, up 24.0% year-over-year, showing increasing adoption of their home-based model. The full-year 2025 net revenue guidance was updated to a range of $271 million to $273 million. This scale allows them to negotiate better terms and drive system-wide efficiencies, which is what alerts CMS to the data we've built up, as noted in their Q1 2025 commentary. It's about shifting the site of care to a more cost-effective setting.
Reduced hospital readmissions for health systems and hospitals.
Reducing readmissions is a major lever for cost control in healthcare, and Viemed Healthcare's PACE Program is explicitly designed to reduce exacerbations, readmissions, and ER visits through comprehensive, one-on-one patient care and assessments. The general 30-day all-cause hospital readmission rate hovered around 13.9 per 100 index admissions between 2016 and 2020, and the average cost of those readmissions was $16,300 in that period. Viemed Healthcare's model, which combines home ventilation support with licensed Respiratory Therapists (RTs), directly targets this expensive problem. Their focus on chronic respiratory diseases like COPD aims to keep patients stable at home, avoiding the high cost of acute care episodes.
High-touch, technology-enabled in-home care for chronic conditions.
This is where the high-touch model proves its worth by driving patient engagement and compliance, which is critical for managing chronic conditions. You see this commitment reflected in the growth of their patient base, which is the real-time proof of concept. They maintain a high service model supported by clinical practitioners providing therapy, education, and counseling in the home. Here's a look at the patient volume growth as of late 2025:
| Service Line Metric (as of Q3 2025) | Patient Count | Year-over-Year Growth |
|---|---|---|
| PAP Therapy Patients | 31,891 | 63.7% increase |
| Ventilator Patients | 12,372 | 8.8% increase |
The PAP therapy patient count growth to 31,891 as of Q3 2025 shows strong demand for their comprehensive care model, which goes beyond just supplying equipment.
Diversified service lines: respiratory, sleep, and maternal health.
Viemed Healthcare has successfully diversified its revenue mix away from being solely dependent on one area, which is a smart move for stability. The growth of these lighter CapEx businesses is changing the overall margin profile, with the company expecting full-year 2025 Adjusted EBITDA in the range of $60 million to $62 million. Here's the revenue composition from the first quarter of 2025, showing the shift:
- Core ventilator business: 54% of revenue.
- Sleep business: increased to 16% of revenues.
- Staffing business: increased to 10% of revenues.
- Oxygen business: accounted for 10% of revenues.
The sleep business, for instance, saw its PAP therapy patient count increase by 51.4% year-over-year as of June 30, 2025, indicating rapid scaling in that segment.
Improved quality of life and better clinical outcomes for patients.
The ultimate value proposition for the patient is a longer, healthier life at home, and the clinical data supports this. Studies they highlight show that Non-Invasive Ventilation (NIV) treatments can reduce patient mortality by 42% after only six months for COPD and CRF patients. That's a concrete, life-altering number. The company's commitment is to help patients manage their disease, not just treat an acute episode, which translates to a longer, more independent life at home. Finance: draft 13-week cash view by Friday.
Viemed Healthcare, Inc. (VMD) - Canvas Business Model: Customer Relationships
You're looking at how Viemed Healthcare, Inc. (VMD) builds and maintains its connection with the patients and providers it serves as of late 2025. It's a high-touch model, meaning they invest heavily in direct clinical interaction, which is supported by their growing patient base and clinical staff.
Dedicated, high-touch clinical support from RTs.
The clinical team is central to the relationship, ensuring patients get the hands-on care needed for complex respiratory conditions. As of December 31, 2024, Viemed Healthcare employed 404 licensed Respiratory Therapists (RTs), which was approximately 34% of the total company employee count. This focus on clinical personnel is designed to maintain a high service model in the home. The company has shown strong clinical outcomes, reporting a 30-day COPD re-admission rate of 5.7% compared to the industry average of 20-22% in studies. Furthermore, over 93% of their patients report they actually 'Breathe Better' on the treatment program.
Individualized treatment plans for chronic respiratory patients.
Viemed Healthcare, Inc. (VMD) structures care around the specifics of each patient's medical condition, which is critical for reimbursement and outcomes. The patient volumes across key service lines show the scale of this individualized approach as of late 2025:
| Patient Metric | Count as of September 30, 2025 | Year-over-Year Growth |
| PAP Therapy Patients | 31,891 | 63.7% increase |
| Sleep Resupply Patients | 33,518 | 51.4% increase |
| Ventilator Patients | 12,372 | 8.8% increase |
The sleep resupply population of 33,518 surpassed the PAP therapy rental base for the first time in the third quarter of 2025, signaling a successful conversion to recurring relationships.
Automated resupply program for PAP therapy patients.
The recurring revenue stream from supplies is supported by a program designed for ease of use. The sleep resupply segment showed significant acceleration. In the third quarter of 2025, the resupply population grew 51% year-over-year and 33% sequentially. This growth trajectory is expected to continue as newer therapy patients transition into the resupply program. For context, the sleep resupply patient count was 25,246 as of June 30, 2025.
Direct sales force focused on physician and provider referrals.
The sales force acts as the vital link between the company and the referral sources, such as physicians and hospital staff. To support growth, Viemed fortifies this team. The company launched eight new sleep areas since the beginning of 2025, with sales reps specifically tasked to market the sleep program to referral sources. These field-based business development roles spend 80% or more of their time networking and educating referral sources like Pulmonologists, Hospitalists, and Case Managers. The sales strategy focuses on building solid working relationships with these external referral sources geographically located within their assigned territory.
- Sales personnel are required to maintain performance meeting or exceeding sales quotas.
- The sales team partners with clinical and managerial staff to promote services to all referral sources.
- The sales role requires established relationships with Sleep Specialists and physicians.
Viemed Healthcare, Inc. (VMD) - Canvas Business Model: Channels
Direct-to-patient delivery and setup by clinical staff is supported by a workforce that, as of December 31, 2024, included 404 licensed Respiratory Therapists (RTs). This clinical presence supports the delivery of services that generated net revenues of $71.9 million in the third quarter ended September 30, 2025.
Physician and hospital referral networks drive patient volume, evidenced by the total patient base growth. As of September 30, 2025, Viemed Healthcare served 31,891 PAP therapy patients and 12,372 ventilator patients.
The national service footprint covers all 50 U.S. states. This broad reach supports the company's operational scale, which included generating net cash provided by operating activities of $18.4 million in the third quarter of 2025.
Online and phone-based resupply ordering for consumables supports the recurring revenue base. As of June 30, 2025, the sleep resupply patient count was 25,246.
| Metric | Value (Latest Available 2025 Data) | Date Reference |
| Total PAP Therapy Patients | 31,891 | September 30, 2025 |
| Total Ventilator Patients | 12,372 | September 30, 2025 |
| Sleep Resupply Patients | 25,246 | June 30, 2025 |
| Q3 2025 Net Revenues | $71.9 million | September 30, 2025 |
| Base Purchase Price of Lehan's Acquisition | $26 million | July 1, 2025 |
The company's commitment to shareholder value through its channel strategy is also reflected in capital deployment; during the third quarter of 2025, 1,706,380 common shares were repurchased at an average price of $6.68 per share.
Viemed Healthcare, Inc. (VMD) - Canvas Business Model: Customer Segments
You're looking at Viemed Healthcare, Inc. (VMD)'s customer base as of late 2025, and honestly, the story here is about diversification away from the core, but that core is still incredibly strong. The customer segments are clearly defined, moving from the traditional, high-acuity respiratory patient to newer, recurring revenue streams.
The foundation remains the patients needing complex, in-home respiratory support. This includes folks with Chronic Obstructive Pulmonary Disease (COPD) and other serious respiratory diseases who require advanced equipment and clinical oversight. This segment is supported by the company's core competency in respiratory therapy and equipment rental.
The sleep apnea market is exploding for Viemed Healthcare, Inc. This is a massive segment for them, driven by both initial therapy setup and long-term consumables. As of September 30, 2025, the number of patients on PAP (Positive Airway Pressure) therapy was exactly 31,891. That's a significant jump, showing their sales focus is paying off. To be fair, the recurring revenue from supplies is even larger; the sleep resupply patient count hit 33,518 on the same date.
Here's a quick look at the key patient metrics as of the third quarter close:
| Customer Group Metric | Patient Count (as of Q3 2025) | Year-over-Year Growth |
|---|---|---|
| PAP Therapy Patients | 31,891 | +63.7% |
| Ventilator Patients (Severe Respiratory) | 12,372 | +8.8% |
| Sleep Resupply Patients | 33,518 | +51.4% |
Next, you have the institutional customers: Hospitals and health systems. These partners look to Viemed Healthcare, Inc. for post-acute care solutions to manage patient length-of-stay and improve outcomes once a patient leaves the acute setting. The success of this partnership model is evident because the core ventilation business, which serves these systems, now accounts for less than half of the company's total net revenue, signaling a successful shift in focus.
The temporary staffing solutions target healthcare facilities, particularly in Behavioral Health, where demand remains high. While the sleep segment is the current star, the staffing business was a notable contributor, making up 10% of net revenues in the first quarter of 2025, though management noted a mix shift away from lower-margin staffing in Q3 guidance.
The newest, strategically important segment is Maternal health patients. This came online with the acquisition of Lehan's Medical Equipment on July 1, 2025, focusing on breast pumps and related equipment. This group is critical because their payer mix leans heavily toward commercial insurance and Medicaid, offering revenue streams insulated from some of the Medicare reimbursement risks that affect the core business. Lehan's operations represented about 6% of Viemed Healthcare, Inc.'s third-quarter revenue, and management sees this as a significant growth driver heading into 2026.
- COPD/Respiratory Patients (Ventilator reliance)
- Sleep Apnea Patients (PAP therapy and resupply)
- Hospitals/Health Systems (Post-acute discharge management)
- Behavioral Health Facilities (Temporary staffing needs)
- Maternal Health Patients (Post-acquisition focus on breast pumps)
Finance: draft the 2026 budget assumptions for the maternal health segment contribution by next Tuesday.
Viemed Healthcare, Inc. (VMD) - Canvas Business Model: Cost Structure
You're looking at the cost side of the Viemed Healthcare, Inc. (VMD) business model as of late 2025, which is where the rubber meets the road for profitability in this high-touch clinical service space. Honestly, managing the cost of delivering care in the home is the key differentiator here.
The major operating costs are clearly defined by the recent Q3 2025 performance. For the three months ended September 30, 2025, when Viemed Healthcare, Inc. reported net revenues of $71.9 million, the primary cost components were:
- Cost of Revenue (equipment, supplies, and clinical staff) at 42.5% of Q3 2025 revenue.
- Selling, General, and Administrative (SG&A) expenses, which were 44.4% of Q3 2025 revenue.
Here's the quick math: 42.5% of $71.9 million translates to approximately $30.56 million in Cost of Revenue for the quarter, while 44.4% of that revenue is about $31.93 million in SG&A expenses. That leaves a gross margin of 57.5%, which is what they are working to protect as they scale.
The structure of these costs is heavily weighted toward clinical delivery and the necessary infrastructure to support it. You can see the breakdown of key cost drivers below:
| Cost Component Detail | Latest Reported Metric/Amount | Context/Period |
|---|---|---|
| Cost of Revenue Percentage | 42.5% | Q3 2025 Revenue |
| SG&A Percentage | 44.4% | Q3 2025 Revenue |
| Gross Capital Expenditures (Gross CapEx) | $7.6 million | Q3 2025 |
| Net Capital Expenditures (Net CAPEX) | $6.0 million | Q3 2025 (Calculated: $18.4M Op Cash Flow - $12.4M FCF) |
| Total Borrowing Capacity (Credit Facilities) | Up to $90 million | As of late 2025 |
Capital expenditure for purchasing and maintaining medical equipment inventory is a constant drain, though they manage it with financing options. Gross CapEx for Q3 2025 was $7.6 million. What this estimate hides is that they have significant financing available, with existing commercial credit facilities up to $30.0 million, a delayed draw term loan up to $30 million, and an accordion feature for another $30 million, giving them up to $90 million in total borrowing capacity for patient-related CapEx and other needs. They are actively managing this, as evidenced by the Net CAPEX of $6.0 million in Q3 2025, which is lower than the gross spend because they are selling off older assets.
Labor costs for certified Respiratory Therapists and clinical practitioners are central to their high-service model. Viemed Healthcare, Inc. explicitly focuses overhead costs on personnel that service the patient rather than physical location costs, which is smart for scaling. As of December 31, 2024, they employed 404 licensed RTs, representing about 34% of their total employee count. They expect to continue employing more RTs to maintain that high service level as they grow organically.
Costs associated with strategic acquisitions and integration are a factor, especially following the recent Lehan's Medical Equipment deal. Viemed Healthcare, Inc. closed on Lehan's in Q3 2025 for a base purchase price of $26 million, plus estimated contingent payments of $2.2 million. The risk here, as noted in their filings, is the potential for unforeseen or contingent liabilities and the substantial costs and expenses associated with integrating a new business unit, even though the Lehan's results were immediately accretive to net income.
Finance: draft 13-week cash view by Friday.
Viemed Healthcare, Inc. (VMD) - Canvas Business Model: Revenue Streams
You're looking at how Viemed Healthcare, Inc. brings in cash, which is a mix of recurring service fees and product sales, all centered around in-home respiratory care. Honestly, it's about getting paid for the equipment you provide and the clinical services you deliver.
The full-year 2025 Net Revenue guidance reflects this mix, projecting total revenue to be between $271 million and $273 million. This is a key figure to watch as we move toward year-end.
Here's a breakdown of the primary revenue sources Viemed Healthcare, Inc. relies on:
- Rental revenue from non-invasive ventilators (NIV) and other HME.
- Sales and resupply revenue from PAP therapy consumables, which grew 51% year-over-year in Q3 2025.
- Reimbursement from Medicare, Medicaid, and private insurance for services.
- Revenue from maternal health products, like breast pumps, gained through the Lehan's acquisition.
- Healthcare staffing services revenue.
Ventilation remains the cornerstone, but diversification is clearly happening. For the three months ending September 30, 2025, Viemed reported record net revenues of $71.9 million.
The recurring revenue from equipment rentals, particularly for non-invasive ventilators, provides a strong foundation. While ventilation revenue achieved double-digit year-over-year growth for another consecutive quarter, it now accounts for less than half of total revenue. Specifically, in Q3 2025, ventilator rentals made up 48.5% of the total revenue.
The sleep therapy segment is showing significant acceleration. The sales and resupply component is a major driver here. You saw PAP therapy consumables resupply grow a strong 51% year-over-year in Q3 2025, surpassing the PAP rental base for the first time. This growth is supported by a PAP therapy patient count that increased 63.7% year-over-year as of September 30, 2025.
Reimbursement forms the backbone for collecting on these services. You need to know that Medicare represented 41% of the Company's traditional revenue streams for the year ended December 31, 2024. Furthermore, the recent implementation of new national coverage guidelines for at-home ventilation for Medicare Advantage plans should help secure future cash flows.
Viemed Healthcare, Inc. is actively diversifying beyond core respiratory care. The acquisition of Lehan's Medical Equipment on July 1, 2025, brought in new revenue streams. Maternal health products, specifically breast pumps, are now part of the mix and are poised to be a significant growth driver in 2026. Also, the healthcare staffing segment is contributing meaningfully. Services revenue, which includes staffing, saw an increase of $9.5 million, or 88.8%, primarily due to the growth of these healthcare staffing offerings.
To give you a clearer picture of the revenue mix based on recent data points, here's how some of the key components stack up:
| Revenue Component | Specific Metric/Data Point | Reference Period/Context |
| Full-Year 2025 Guidance | $271 million to $273 million | Projected Net Revenue |
| Ventilator Rental Share | 48.5% | Q3 2025 Total Revenue |
| PAP Resupply Growth | 51% | Year-over-year in Q3 2025 |
| Healthcare Staffing Growth | $9.5 million increase (88.8%) | Services Revenue Increase |
| Medicare Reimbursement Share | 41% | Year Ended December 31, 2024 (Traditional Revenue) |
| Q3 2025 Total Revenue | $71.9 million | Three Months Ended September 30, 2025 |
The growth in patient volumes directly translates to revenue. As of September 30, 2025, the active ventilator patient count stood at 12,372, an 8.8% increase over September 30, 2024. The PAP therapy patient count reached 31,891, showing a massive 63.7% increase over the prior year.
Finance: draft 13-week cash view by Friday.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.